Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance

[1]  J. Hilkens,et al.  Insulin receptor substrate 4 (IRS4) is a constitutive active oncogenic driver collaborating with HER2 and causing therapeutic resistance , 2017, Molecular & cellular oncology.

[2]  J. Hilkens,et al.  IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation , 2016, Nature Communications.

[3]  N. Rosenfeld,et al.  The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes , 2016, Nature Communications.

[4]  G. Hortobagyi,et al.  Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer , 2016, Oncotarget.

[5]  Steven J. M. Jones,et al.  Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.

[6]  Xiaoxin Zhang,et al.  The roles of ERAS during cell lineage specification of mouse early embryonic development , 2015, Open Biology.

[7]  R. Bernards,et al.  PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Brennan,et al.  Sleeping Beauty Mouse Models Identify Candidate Genes Involved in Gliomagenesis , 2014, PloS one.

[9]  Linzhao Cheng,et al.  Stimulation of Somatic Cell Reprogramming by ERas‐Akt‐FoxO1 Signaling Axis , 2014, Stem cells.

[10]  C. Perou,et al.  Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies , 2013, Proceedings of the National Academy of Sciences.

[11]  L. Vatten,et al.  Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients , 2013, Breast Cancer Research and Treatment.

[12]  A. Taghian,et al.  Fat necrosis of the breast in the accelerated partial breast irradiation era: the need for a universal grading system , 2013, Breast Cancer Research and Treatment.

[13]  M. Reinders,et al.  Analysis of Tumor Heterogeneity and Cancer Gene Networks Using Deep Sequencing of MMTV-Induced Mouse Mammary Tumors , 2013, PloS one.

[14]  C. Perou,et al.  The genomic landscape of breast cancer as a therapeutic roadmap. , 2013, Cancer discovery.

[15]  S. Ramaswamy,et al.  A Molecular Roadmap of Reprogramming Somatic Cells into iPS Cells , 2012, Cell.

[16]  S. Chandarlapaty,et al.  Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer , 2012, Clinical Cancer Research.

[17]  R. Stephens,et al.  Genes affected by mouse mammary tumor virus (MMTV) proviral insertions in mouse mammary tumors are deregulated or mutated in primary human mammary tumors , 2012, Oncotarget.

[18]  E. Cuppen,et al.  High-throughput semiquantitative analysis of insertional mutations in heterogeneous tumors. , 2011, Genome research.

[19]  A. V. D. van den Heuvel,et al.  Novel Common Integration Sites Targeted by Mouse Mammary Tumor Virus Insertion in Mammary Tumors Have Oncogenic Activity , 2011, PloS one.

[20]  T. Joh,et al.  ERas enhances resistance to CPT-11 in gastric cancer. , 2011, Anticancer research.

[21]  Zhen Jia,et al.  PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib , 2011, BMC Cancer.

[22]  Hua Guo,et al.  PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. , 2010, The American journal of pathology.

[23]  E. Kubota,et al.  Resistance to chemotherapeutic agents and promotion of transforming activity mediated by embryonic stem cell-expressed Ras (ERas) signal in neuroblastoma cells. , 2010, International journal of oncology.

[24]  T. Joh,et al.  Tumorigenesis and Neoplastic Progression Role of ES Cell-Expressed Ras ( ERas ) in Tumorigenicity of Gastric Cancer , 2010 .

[25]  Eunjoon Kim,et al.  Selected SALM (Synaptic Adhesion-Like Molecule) Family Proteins Regulate Synapse Formation , 2010, The Journal of Neuroscience.

[26]  J. Baselga,et al.  Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G. Hortobagyi,et al.  Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. Sawada,et al.  Expression of ERas oncogene in gastric carcinoma. , 2009, Anticancer research.

[29]  N. Hynes,et al.  ErbB receptors and signaling pathways in cancer. , 2009, Current opinion in cell biology.

[30]  Violeta Serra,et al.  Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. , 2008, Cancer research.

[31]  R. Wenthold,et al.  Synaptic adhesion-like molecules (SALMs) promote neurite outgrowth , 2008, Molecular and Cellular Neuroscience.

[32]  R. Callahan,et al.  Common Integration Sites for MMTV in Viral Induced Mouse Mammary Tumors , 2008, Journal of Mammary Gland Biology and Neoplasia.

[33]  M. Sliwkowski,et al.  A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. , 2008, Cancer research.

[34]  G. Mills,et al.  A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. , 2007, Cancer cell.

[35]  Jos Jonkers,et al.  MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer , 2007, Nature Genetics.

[36]  J. Hilkens.  Recent translational research: Oncogene discovery by insertional mutagenesis gets a new boost , 2006, Breast Cancer Research.

[37]  J. Thomson,et al.  Human ERas Gene Has an Upstream Premature Polyadenylation Signal That Results in a Truncated, Noncoding Transcript , 2005, Stem cells.

[38]  J. Colicelli,et al.  Human RAS Superfamily Proteins and Related GTPases , 2004, Science's STKE.

[39]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[40]  K. Knutson,et al.  neu Antigen-Negative Variants Can Be Generated after neu-Specific Antibody Therapy in neu Transgenic Mice , 2004, Cancer Research.

[41]  Takeshi Suzuki,et al.  RTCGD: retroviral tagged cancer gene database , 2004, Nucleic Acids Res..

[42]  R. Cardiff,et al.  Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. , 2003, Cancer research.

[43]  F. Maurer,et al.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. Yamanaka,et al.  Role of ERas in promoting tumour-like properties in mouse embryonic stem cells , 2003, Nature.

[45]  Robert D Cardiff,et al.  Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. , 2002, The American journal of pathology.

[46]  M. Rudnicki,et al.  Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[47]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[48]  R. Nusse.  Insertional mutagenesis in mouse mammary tumorigenesis. , 1991, Current topics in microbiology and immunology.

[49]  P. Jolicoeur,et al.  Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.

[50]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[51]  E. Soeda,et al.  The human c-Ha-ras2 is a processed pseudogene inactivated by numerous base substitutions. , 1984, Nucleic acids research.